30 Day Trial

Anika Therapeutics Reports 3Q18 Revenue of $24.1MM, +0.4% vs. 3Q17

Share:

Anika Therapeutics posts 3Q18 orthobiologic revenue of $24.1MM, +0.4% vs. 3Q17.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.